This article is more than 5 years old. Information may no longer be current.
Notal Vision completes $25 million in funding
Ganot Capital has extended a funding round to Notal Vision to $25 million to support the growth of the company’s ForeseeHome AMD monitoring program, according to a press release.
“Pursuing additional funding has allowed us to expand our ForeseeHome field-based sales team,” Kester Nahen, PhD, Notal Vision CEO, said in the release. “We have a proven model that includes low-cost medical devices, an effective artificial intelligence-driven decision support solution and a dependable clinical patient engagement platform. With the additional investment, we believe we will be able to prove that partnering with accounts as an extension of their practice will drive deeper adoption of our home diagnostic services.”
The funding also assists the company’s other pipeline technologies such as the Home OCT platform, which received FDA breakthrough device status in 2018.